71 related articles for article (PubMed ID: 25128389)
1. Mesenchymal change and drug resistance in neuroblastoma.
Naiditch JA; Jie C; Lautz TB; Yu S; Clark S; Voronov D; Chu F; Madonna MB
J Surg Res; 2015 Jan; 193(1):279-88. PubMed ID: 25128389
[TBL] [Abstract][Full Text] [Related]
2. The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro.
Piskareva O; Harvey H; Nolan J; Conlon R; Alcock L; Buckley P; Dowling P; Henry M; O'Sullivan F; Bray I; Stallings RL
Cancer Lett; 2015 Aug; 364(2):142-55. PubMed ID: 25960282
[TBL] [Abstract][Full Text] [Related]
3. Differential drug sensitivity of human neuroblastoma cells.
Spengler BA; Ross RA; Biedler JL
Cancer Treat Rep; 1986 Aug; 70(8):959-65. PubMed ID: 3731152
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.
Slovak ML; Hoeltge GA; Dalton WS; Trent JM
Cancer Res; 1988 May; 48(10):2793-7. PubMed ID: 2896069
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
Lautz TB; Naiditch JA; Clark S; Chu F; Madonna MB
J Pediatr Surg; 2012 Jun; 47(6):1267-71. PubMed ID: 22703804
[TBL] [Abstract][Full Text] [Related]
6. Establishment of an in vitro model for cisplatin resistance in human neuroblastoma cell lines.
Ireland CM; Pittman SM; Jones SL; Harnett PR
Anticancer Res; 1994; 14(6B):2397-403. PubMed ID: 7872659
[TBL] [Abstract][Full Text] [Related]
7. The effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma.
Lautz TB; Jie C; Clark S; Naiditch JA; Jafari N; Qiu YY; Zheng X; Chu F; Madonna MB
PLoS One; 2012; 7(7):e40816. PubMed ID: 22829886
[TBL] [Abstract][Full Text] [Related]
8. Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression.
Blaheta RA; Daher FH; Michaelis M; Hasenberg C; Weich EM; Jonas D; Kotchetkov R; Doerr HW; Cinatl J
BMC Cancer; 2006 Dec; 6():294. PubMed ID: 17181871
[TBL] [Abstract][Full Text] [Related]
9. Effects of retinoic acid on proliferation, apoptosis, cytotoxicity, migration, and invasion of neuroblastoma cells.
Voigt A; Zintl F
Med Pediatr Oncol; 2003 Apr; 40(4):205-13. PubMed ID: 12555246
[TBL] [Abstract][Full Text] [Related]
10. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126.
Eppstein AC; Sandoval JA; Klein PJ; Woodruff HA; Grosfeld JL; Hickey RJ; Malkas LH; Schmidt CM
J Pediatr Surg; 2006 Jan; 41(1):252-9. PubMed ID: 16410143
[TBL] [Abstract][Full Text] [Related]
11. Differential sensitivity of p44/p42-MAPK- and PI3K/Akt-targeted neuroblastoma subtypes to arsenic trioxide.
Yousefi M; Ghaffari SH; Zekri A; Ghanizadeh-Vesali S; Hosseini E; Rostami M; Hassani S; Alimoghaddam K; Ghavamzadeh A
Neurochem Int; 2013 Dec; 63(8):809-17. PubMed ID: 24161621
[TBL] [Abstract][Full Text] [Related]
12. Environmental endocrine disruptors promote invasion and metastasis of SK-N-SH human neuroblastoma cells.
Zhu H; Zheng J; Xiao X; Zheng S; Dong K; Liu J; Wang Y
Oncol Rep; 2010 Jan; 23(1):129-39. PubMed ID: 19956873
[TBL] [Abstract][Full Text] [Related]
13. Activation of a prometastatic gene expression program in hypoxic neuroblastoma cells.
Poomthavorn P; Wong SH; Higgins S; Werther GA; Russo VC
Endocr Relat Cancer; 2009 Sep; 16(3):991-1004. PubMed ID: 19423615
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-beta 1 differentially regulates proliferation, morphology, and extracellular matrix expression by three neural crest-derived neuroblastoma cell lines.
Rogers SL; Cutts JL; Gegick PJ; McGuire PG; Rosenberger C; Krisinski S
Exp Cell Res; 1994 Apr; 211(2):252-62. PubMed ID: 8143771
[TBL] [Abstract][Full Text] [Related]
15. Expression of the smg p25A (a ras p21-like GTP-binding protein) gene in human neuroblastoma cell lines and tumor tissues.
Sano K; Nakamura H; Mabuchi S; Tanaka T; Nakagawara A; Takai Y
Cancer Res; 1990 Nov; 50(22):7242-5. PubMed ID: 2121331
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic effects of m-[131I]- and m-[125I]iodobenzylguanidine on the human neuroblastoma cell lines SK-N-SH and SK-N-LO.
Bruchelt G; Girgert R; Buck J; Wolburg H; Niethammer D; Treuner J
Cancer Res; 1988 Jun; 48(11):2993-7. PubMed ID: 3365688
[TBL] [Abstract][Full Text] [Related]
17. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway.
Flahaut M; Meier R; Coulon A; Nardou KA; Niggli FK; Martinet D; Beckmann JS; Joseph JM; Mühlethaler-Mottet A; Gross N
Oncogene; 2009 Jun; 28(23):2245-56. PubMed ID: 19421142
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetic alterations associated with the acquisition of doxorubicin resistance: possible significance of chromosome 7 alterations.
Slovak ML; Hoeltge GA; Trent JM
Cancer Res; 1987 Dec; 47(24 Pt 1):6646-52. PubMed ID: 3677098
[TBL] [Abstract][Full Text] [Related]
20. HMGI(Y) and HMGI-C genes are expressed in neuroblastoma cell lines and tumors and affect retinoic acid responsiveness.
Giannini G; Di Marcotullio L; Ristori E; Zani M; Crescenzi M; Scarpa S; Piaggio G; Vacca A; Peverali FA; Diana F; Screpanti I; Frati L; Gulino A
Cancer Res; 1999 May; 59(10):2484-92. PubMed ID: 10344762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
